Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC
2 Phase 3 Trial in RCC: Atezolizumab Plus Cabozantinib After Progression With ICIs
3 Atezolizumab/Nab-Paclitaxel Induces Clinically Meaningful OS Benefit in PD-L1+ Locally Advanced or Metastatic TNBC
4 CASPIAN Trial Results Offer Another Option for SCLC
5 Gene Mutations and Transcriptional Signatures Correlate With Response to Therapy in Advanced Renal Cell Carcinoma
6 EMUC 2020: A Subgroup Analysis from the IMvigor130 Study in Patients with Upper Tract vs. Lower Tract Local...
7 Health Beat: New immunotherapy treatment for lung cancer
8 Atezolizumab Leads to Longer OS for Some Types of Advanced NSCLC, Study Says
9 Atezolizumab Appears Effective for Patients with NSCLC with High PD-L1 Expression
10 FDA Approves Merck's Keytruda, Agilent CDx in PD-L1-High Triple-Negative Breast Cancer
11 Atezolizumab Plus Paclitaxel in Breast Cancer: FDA Issues Safety, Efficacy Alert
12 In Patients With NSCLC Relapsing Shortly After Frontline Therapy Initiation, Ramucirumab Combination Impresses
13 FDA Approves Atezolizumab for PD-L1 High NSCLC
14 Triple-Negative Breast Cancer Treatments Continue to Evolve
15 Tecentriq-Avastin Combo Approved in Europe for Advanced or...
16 Aggarwal Examines Nivolumab Plus Ipilimumab in First-Line NSCLC
17 Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting
18 FDA Issues Alert for Atezolizumab, Paclitaxel Combination in Patients with TNBC
19 Renal Cancer Study Finds Disease Subsets Determine Response to Angiogenesis Blockade Therapy
20 Roche gets EC approval for Tecentriq-Avastin combo to treat liver cancer
21 VIDEO: Tiragolumab plus atezolizumab confers benefit for certain patients with NSCLC
22 Unlocking the Potential of Targeted Treatment Options for HCC
23 Europe approves Roche's Tecentriq liver cancer combination
24 Atezolizumab regimen fails to extend PFS in triple-negative breast cancer subset
25 Frontline Atezolizumab Plus Paclitaxel Misses Primary End Point in TNBC Trial
26 Addition of Atezolizumab Improves pCR in Early TNBC, Irrespective of PD-L1 Status
27 Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
28 New Strategies Enhance Care in mUC
29 Atezolizumab plus chemotherapy improves PFS in metastatic urothelial carcinoma
30 FDA Approves Atezolizumab Plus Cobimetinib and Vemurafenib for Advanced Melanoma
31 Atezolizumab Plus Cobimetinib Improves Cancer Control for Patients with Biliary Tract Cancer
32 FDA Grants Priority Review to Atezolizumab to Treat Advanced Non-Small Cell Lung Cancer
33 Atezolizumab regimen improves outcomes in early triple-negative breast cancer
34 Comparative Effectiveness of Systemic Treatments for Advanced HCC
35 FDA Approves Atezolizumab/Bevacizumab Combination for HCC
36 FDA Alert: Efficacy Concerns with Atezolizumab Plus Paclitaxel for Breast Cancer
37 Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC
38 Atezolizumab/Bevacizumab Approval Leaves Second-Line Questions in HCC
39 Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer
40 Atezolizumab Regimen Improves OS in Frontline Extensive-Stage Small Cell Lung Cancer, Regardless of Biomarker Status
41 Atezolizumab plus cobimetinib improves PFS in biliary tract cancer
42 Atezolizumab/Bevacizumab Approved in Europe for Advanced or Unresectable HCC
43 Immunotherapy Leads the Way in Lung Cancer, but Creates Complex Treatment Decisions
44 Atezolizumab combination improves survival in HCC
45 Systemic Therapy Advances Provide More Treatment Options in HCC
46 Novel Anti-TIGIT Agent Tiragolumab Plus Atezolizumab Impresses in NSCLC
47 Atezolizumab Plus Bevacizumab/Chemo Does Not Significantly Improve PFS for Ovarian Cancer
48 Phase 3 trial of atezolizumab for urothelial cancer misses primary endpoint
49 Atezolizumab Combo Approved in UK for Small Cell Lung Cancer
50 Addition of atezolizumab to enzalutamide fails to extend OS in metastatic castration-resistant prostate cancer
51 Neoadjuvant atezolizumab, chemotherapy improve outcomes in triple-negative breast cancer
52 Cabozantinib Plus Atezolizumab Shows Promising Clinical Activity in Advanced Clear Cell Renal Cell Carcinoma
53 Survival Benefit Seen With Atezolizumab-Bevacizumab Combo in Unresectable HCC
54 NICE Recommends Atezolizumab for Extensive-stage Small Cell Lung Cancer
55 Atezolizumab Market (2020-2026) | Where Should Participant Focus To Gain Maximum ROI | Exclusive Report By DataIntelo
56 ASCO Systemic Therapy Guideline Developed for Advanced HCC
57 Atezolizumab Plus Cabozantinib Shows Promising Early Results in ccRCC
58 Atezolizumab Market Global Briefing and Future Outlook 2020 to 2025
59 Atezolizumab/Bevacizumab Plus Chemotherapy Sustains Survival Benefit After 20 Months in EGFR+ NSCLC
60 PPIs may affect responses to atezolizumab in patients with urothelial cancer
61 Atezolizumab combination extends PFS in BRAF V600-mutant advanced melanoma
62 FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma
63 Atezolizumab + bevacizumab approved by FDA for unresectable HCC
64 Antibiotics linked to worse survival outcomes with atezolizumab in bladder cancer
65 Addition of Atezolizumab to Chemo May Not Increase Treatment Burden
66 Cabozantinib Plus Atezolizumab Shows Promise in mCRPC
67 FDA Approves Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel for Lung Cancer Subset
68 Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study
69 Bevacizumab + Atezolizumab: Survival and Quality-of-Life Benefits in Advanced Liver Cancer Spur Regulatory Approval
70 Atezolizumab plus bevacizumab improves survival outcomes vs. sorafenib in unresectable HCC
71 OS Benefit for First-Line Atezolizumab in Metastatic NSCLC With High PD-L1 Expression
72 Frontline 4-Drug Atezolizumab Regimen Shows Tolerability and Minimal Treatment Burden in NSCLC
73 Atezolizumab Added to Chemo Delays Metastatic Bladder Cancer Progression
74 Immune Checkpoint Inhibitors Market to Inspire a Growth up to US$ 40,882.6 Million by 2026 – Coherent Market Insights
75 Tiragolumab/Atezolizumab Shows Early First-in-Human Efficacy in Frontline PD-L1+ NSCLC
76 Atezolizumab may increase overall survival in patients with metastatic non-small-cell lung cancer
77 Combination Therapy With Cabozantinib and Atezolizumab Gains Foothold in Urothelial Carcinoma
78 FDA Approves Frontline Atezolizumab Plus Chemo for Metastatic Non-Squamous NSCLC
79 Proton Pump Inhibitor Use May Impact Response to Atezolizumab in Patients with Bladder Cancer
80 Dr. Kim on the Safety Profile of Atezolizumab/Bevacizumab in HCC
81 FDA OKs Atezolizumab Plus Bevacizumab for Frontline Treatment of Advanced Liver Cancer
82 Atezolizumab and Nab-Paclitaxel for the Treatment of Triple-Negative Breast Cancer
83 Atezolizumab Misses Disease-Free Survival End Point in Muscle-Invasive Urothelial Cancer
84 Atezolizumab and Its Many Uses
85 Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
86 Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer
87 Tecentriq (Atezolizumab)
88 Chemoimmunotherapy Transforms the Lung Cancer Armamentarium
89 Personalized Cancer Vaccine with Atezolizumab Shows Promise in Advanced Solid Tumors
90 Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors
91 Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer
92 CAR-T plus atezolizumab safe, effective in refractory diffuse large B-cell lymphoma
93 Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC
94 FDA Approval Sought for Frontline Atezolizumab Plus Bevacizumab in HCC
95 Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC
96 Atezolizumab fails to improve response in triple-negative breast cancer
97 Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers
98 Bladder Cancer Therapeutics Market Current Scenario 2020 – Global Size, Trends, Growth By Top Leaders, Dynamic, Business Opportunity and Challenges From Up to 2026
99 Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer
100 Atezolizumab/Bevacizumab Shows Comparable Activity in Older Patients With Advanced HCC